519results about "Radioactive preparation forms" patented technology

The present invention discloses a medical microsphere and its preparation method and application. The medical microsphere includes phenolic resin microspheres and radioactive metal elements loaded on the phenolic resin microspheres; the average particle size of the phenolic resin microspheres is 1 to 150 μm. The medical microsphere in the present invention can not only achieve local cell killing in the blood vessels of a specific part, but also effectively avoid the occurrence of fragmentation; further, the medical microsphere has a good loading rate and an extremely low exudation loss rate, which can meet the loading and safety requirements of radioactive elements; in addition, the preparation method of the medical microsphere is simple.

The invention discloses a metal polyphenol network modified drug-loaded radioactive microsphere as well as a preparation method and application thereof, radionuclides are labeled on different microspheres by a precipitation method or an adsorption method, and the metal polyphenol network is modified on the surface of the radioactive microsphere to improve the nuclide labeling stability and the synchronous drug loading capability of the radioactive microsphere. Subsequently, medicine molecules can be adsorbed to the modified radioactive microspheres to obtain the metal polyphenol network modified medicine-carrying radioactive microspheres. The metal polyphenol network modified drug-loaded radioactive microspheres prepared by the invention can solve the problems of radionuclide non-target shedding and DNA damage repair caused by nuclear drugs, avoid secondary drug administration, ensure that drugs directly and accurately reach tumor targets, and improve the drug delivery efficiency. And the selective internal irradiation therapy based on radioactive microsphere mediation is further promoted to play a more effective tumor treatment effect.

The invention discloses a lung deep targeted delivery method and a micro-robot cluster, and the method comprises the following steps: preparing microgel particles containing magnetic particles, developing particles and cargos, and combining the prepared microgel particles to obtain the micro-robot cluster; the micro-robot cluster is controlled to move, climb and reconstruct in a non-fluid environment, so that the micro-robot cluster moves in a pipeline environment with holes; controlling the micro-robot cluster to move in the lung sample under the guidance of X-rays, and delivering the micro-robot cluster to a target bronchus of the lung sample; or the micro-robot cluster is controlled to be delivered in the target lung under the guidance of computed tomography imaging, and the wrapped goods are released in the target bronchus; the micro robot cluster provided by the invention can realize targeted delivery in a lung environment full of air, a lung environment with a mucus layer and a lung deep target bronchus.

The invention discloses a preparation method of a 32P-loaded ultrathin flaky chitosan hydrogel applicator. The preparation method comprises the following steps: (1) preparing a chitosan aqueous solution; (2) dropwise adding methacrylic anhydride into the chitosan aqueous solution for reaction to obtain methylacryloylated chitosan; (3) preparing a methylacryloyl chitosan aqueous solution; (4) adding 2-hydroxy-4 '-(2-hydroxyethoxy)-2-methyl propiophenone into the methylacryloylated chitosan aqueous solution to obtain a chitosan hydrogel precursor solution, and (5) coating the inner wall of a mold made of a polytetrafluoroethylene material with a super-hydrophilic coating; (6) adding the Na2H32PO4 aqueous solution and the chitosan hydrogel precursor solution into a mold, stirring, and carrying out illumination curing; and (7) taking out the cured hydrogel and packaging the hydrogel between two layers of transparent adhesive tapes. According to the application, the ultrathin hydrogel applicator can be prepared, so that the blocking of the hydrogel material to rays is reduced, and the curative effect of the applicator is enhanced.

Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity for innate immune cells are provided.

The invention provides a preparation method of Al18F tracer integrated freeze-dried powder, a kit and application thereof, and the preparation method comprises the following steps: dissolving 1-10 mg of a precursor by using deionized water, adding a pH buffer solution with the concentration of 0.2-0.5 M and an AlCl3 solution with the concentration of 10 mM, with the ratio of the amount of substance of AlCl3 to the amount of substance of the precursor being 0.8-1.0, then continuously adding a stabilizer solution with the concentration of 0.5 M and 1-4 mg of an excipient, and uniformly stirring to obtain the Al18F tracer integrated freeze-dried powder. And finally, adding deionized water to enable the concentration of the precursor to be 0.5-1.0 mM, uniformly mixing the solution, sub-packaging the solution into 1.5 mL cryopreservation tubes or 2 mL penicillin bottles according to a certain volume, and then putting the cryopreservation tubes or the penicillin bottles into a vacuum freeze dryer to remove water at a low temperature to obtain powder or freeze-dried cakes, and the container is a freeze-dried powder / cake storage container and is used for storing the freeze-dried powder / cakes. Meanwhile, the reaction container is also used during radioactive labeling.

Disclosed herein are methods and systems for the use of extraction chromatography resins to concentrate Ac from dilute solutions that may contain Th isotopes and / or other isotopes, such as Ra. As disclosed herein, at least some extraction chromatography resins strongly retain trivalent actinides between 4 and 6 M HNO3 that can be recovered in good yields with small volumes of dilute acids. These small volumes of acid eluents result in significant concentration of the solution of the trivalent / certain tetravalent ions, such that they can be further processed without requiring lengthy evaporation steps that are utilized in standard Ac concentration methods.

The invention belongs to the field of tumor drugs, and discloses a radioactive hydrogel based on crosslinking of sodium alginate and metal ions and a preparation method and application thereof.The preparation method of the radioactive hydrogel comprises the following steps that lutetium chloride and metal ions are mixed, and a metal ion mixed solution is obtained; doping 177Lu radioactive isotope into the obtained metal ion mixed solution to obtain a metal ion cross-linking agent; and injecting a metal ion cross-linking agent into the sodium alginate solution under a vortex condition, centrifuging, and discarding the supernatant to obtain the radioactive hydrogel. The radioactive hydrogel (177Lu-RH) provided by the invention has good in-tumor colonization capability, can be directly injected into a tumor to realize local radiotherapy, has good radioactive stability, and can be stably retained at a tumor part for more than 120 hours, so that the stability of radioactive labeling in a treatment process is ensured.

The present invention relates to polymeric radiotherapeutic particles, compositions and methods for producing same, wherein the radionuclide is an alpha and / or beta-emitting radionuclide. The invention also relates to the use of said particle and compositions, in the treatment of cancer and their use in locoregional radiotherapy, brachytherapy and transarterial radioembolization.

The invention relates to the technical field of radiopharmaceutical preparations, in particular to yttrium [90Y] microsphere injection as well as a preparation method and application thereof. The preparation method of the yttrium [90Y] microsphere injection comprises the following steps: S1, uniformly mixing a radioactive stock solution and an yttrium sulfate solution, stirring and mixing with resin microspheres, and washing to obtain yttrium [90Y] microspheres; s2, stirring and mixing a sodium phosphate solution and the yttrium [90Y] microspheres, taking out 1 / 3 volume of clear liquid, carrying out suction filtration on the residual clear liquid, and mixing the taken clear liquid with the yttrium [90Y] microspheres to obtain mixed liquid; and S3, stirring and mixing the sodium dihydrogen phosphate solution and the mixed liquid, taking out 4 / 10 volume of clear liquid, carrying out suction filtration on the residual clear liquid, mixing the taken clear liquid with yttrium [90Y] microspheres, washing, filling and sealing, and sterilizing to obtain the yttrium [90Y] microsphere injection. The labeling rate of yttrium [90Y] in the produced yttrium [90Y] microsphere injection is high.

A method of generating an emulsion for treating a patient. The method includes generating a water-based solution carrying an agent which turns into a hydrogel by addition of calcium ions. Radium radionuclides are added to the water-based solution in a concentration sufficient for radiotherapy. After adding the radium to the water-based solution, the water-based solution is mixed with an emulsifier and an oil.

The present application relates to the technical field of radiopharmaceutical preparation, specifically relates to an yttrium [90Y] microsphere and preparation method therefor and use thereof. The yttrium [90Y] microsphere comprises a polystyrene sulfonic acid type resin microsphere and yttrium-90 adsorbed within the polystyrene sulfonic acid type resin microsphere. The use of polystyrene sulfonic acid type resin microsphere to adsorb yttrium-90 has significantly improved adsorption strength, significantly improved safety during preparation and use, and has a good killing effect on tumor cells.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and / or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.

The present disclosure relates to enriched and stable radiopharmaceutical compositions comprising [225Ac]Ac-DOTA-TATE.

The present disclosure relates to stable compositions comprising a radiolabeled compound, and related pharmaceutical compositions and methods of manufacture. Such compositions are useful in both the diagnostic imaging of and the treatment of diseases (e.g., cancer).

Systems and methods are disclosed for determining the spatial distributions of radionuclides in tissue samples via mass spectrometry imaging. After administration of a radiopharmaceutical that contains a radionuclide, a mass spectrometry imaging system, such as an imaging mass cytometer or a multiplexed ion beam imaging system, is employed to interrogate a tissue sample to obtain a dataset. The radiopharmaceutical includes, or generates via radioactive decay of the radionuclide, a metal isotope detectable by the mass spectrometry imaging system. The dataset is processed to determine a spatial distribution of the metal isotope within the tissue sample, thereby characterizing the spatial distribution of the radionuclide delivered within the tissue sample. The tissue sample may be stained with a biomarker reagent that includes an additional metal isotope attached to a biomarker ligand, enabling the spatially multiplexed and co-registered analysis. The present methods can be adapted to infer and assess localization of non-radioactive pharmaceuticals.

The present disclosure relates to pharmaceutical compositions comprising [61Cu]Cu-NODAGA-LM3 or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a somatostatin receptor subtype 2 (SST2)-expressing tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

The present disclosure generally relates to materials, processes, generators, and / or systems, for generating radioisotope. The present disclosure also generally relates to ceramic materials comprising radioisotope suitable for use in a radioisotope generator. The present disclosure also generally relates to processes, generators and / or systems, for producing and capturing radioisotope. The present disclosure also generally relates to the preparation of radioisotope solutions for use in radiopharmacy and / or other clinical applications.

The application provides a radionuclide nanohydrogel microneedle and a preparation method and application thereof, and belongs to the field of nanobiomedicine. 32 P-labeled calcium phosphate, which is formed by a biomimetic reaction of Ag2S@Ca 32 P nanoparticles, and a base layer which is a base matrix and comprises hyaluronic acid 32 P nanohydrogel microneedle can release Ag2S nanoparticles in response to a weakly acidic tumor environment, and under the irradiation of near-infrared light, the photothermal conversion efficiency can effectively kill bacteria, effectively improve the tumor hypoxic environment, enhance the treatment effect of radionuclides, play an antibacterial and wound healing promoting role in melanoma defect repair, and maximize the inhibition of tumor growth and tumor recurrence.

Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and / or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.

The present invention relates to MOFs for radiotherapy. More specifically, the present invention provides: a particle comprising an MOF, optionally at least one targeting moiety, and at least one beta-emitting radionuclide; a composition comprising the particles; said particles or composition for use as a medicament; said particles or compositions for use in a method of treating a proliferative disease; and a kit comprising a particle comprising an MOF, optionally a targeting moiety, and a beta-emitting radionuclide.

The invention belongs to the technical field of hydrogel, and provides photo-crosslinking hydrogel, a preparation method and application thereof, a radionuclide preparation and an application. The photo-crosslinking hydrogel with the adhesion comprises a crosslinking network structure formed by dopamine modified methacrylic acid gelatin and o-nitrobenzyl sulfide light trigger modified hyaluronic acid, has injectability, can be gelatinized after being triggered by light, is high in adhesion, and can be used for preparing the hydrogel while improving the mechanical property of the hydrogel. And the hydrogel can bear larger deformation and maintain better elasticity, so that physical-chemical synergistic enhanced adhesion is realized, and instant and firm adhesion with biological tissues can be realized. Furthermore, the photo-crosslinked hydrogel can be used as a carrier, for example, a radionuclide-loaded preparation, or a patch containing radionuclide is prepared, or the photo-crosslinked hydrogel can also be used as a hemostatic material.

Liposomes encapsulating a radioisotope can be used in the treatment of cancers including, but not limited to, leptomeningeal metastases. In an embodiment, liposome encapsulating a radioisotope comprising (186Re) obisbemeda can be administered to a patient through an Ommaya reservoir. The therapies can include imaging the liposome encapsulating a radioisotopе concomitant or subsequent to administration. Longitudinal analysis of the presence of tumor cells and biomarkers can be used to inform treatment strategy.

The present disclosure generally relates to materials, processes, generators, and / or systems, for generating radioisotope. The present disclosure also generally relates to ceramic materials comprising radioisotope suitable for use in a radioisotope generator. The present disclosure also generally relates to processes, generators and / or systems, for producing and capturing radioisotope. The present disclosure also generally relates to the preparation of radioisotope solutions for use in radiopharmacy and / or other clinical applications.

The invention discloses an iron-based metal nano diagnosis and treatment agent as well as a preparation method and application thereof. The iron-based metal nano diagnosis and treatment agent comprises an iron-based metal nano material and a diagnosis and treatment agent loaded with therapeutic nuclide 177Lu and / or a micromolecular chemotherapeutic drug F16. The iron-based metal nano diagnosis and treatment agent contains an iron element, can be used for MRI imaging and can induce tumor ferroptosis at the same time, radionuclide 177Lu can emit gamma rays for SPECT imaging and can emit beta rays for tumor internal radiotherapy, tumor mitochondria targeting small molecule medicine F16 has the fluorescence characteristic and can be used for tumor real-time fluorescence imaging, and the application range is wide. Meanwhile, a mitochondrial targeting tumor killing effect is achieved. Therefore, the iron-based metal nano diagnosis and treatment agent disclosed by the invention can realize comprehensive collaborative treatment of intratumor radiotherapy, targeted chemotherapy and ferroptosis under the guidance of MRI (Magnetic Resonance Imaging), SPECT (Single Photon Emission Computed Tomography) and multi-mode imaging of fluorescence imaging, and improves the precise diagnosis and treatment of tumors.

The invention relates to a 14C urea pharmaceutical composition for helicobacter pylori diagnosis and application of the 14C urea pharmaceutical composition. The 14C urea pharmaceutical composition comprises 14C urea, 12C urea, citric acid, malic acid and mannitol. According to the invention, the 12C urea and the 14C urea are added together, so that the radioactivity can be ensured, the stability of the medicine can be improved, and the auto-radiolysis of 14C can be reduced. Besides, citric acid, malic acid and mannitol have a remarkable synergistic effect in the aspect of improving the radioactive activity and radiochemical purity of the composition, the stability of the 14C urea pharmaceutical composition can be improved, meanwhile, the activity of urease generated by helicobacter pylori can be improved, and the detection sensitivity and detection efficiency are further guaranteed.

The invention discloses a radioactive medical isotope Ra-223 stably-labeled rare earth nano diagnosis and treatment preparation as well as a preparation method and application thereof. According to the invention, by constructing a dual protection mechanism of the shell layer and the functional biomolecular layer, the Ra-223 is effectively packaged, the recoil nuclei of the Ra-223 are reserved at the tumor part and are prevented from escaping to the surrounding environment of the tumor, the safety of the Ra-223 treatment process can be enhanced, the radioactive energy is ensured to accurately act on the focus, and the treatment effect of the Ra-223 is improved. Meanwhile, the damage risk to healthy tissues is minimized.

The present invention relates to triglyceride analogs labeled with radioisotopes, or salts thereof, for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging. In addition, the present invention relates to compositions comprising the radiolabeled triglyceride analog, or a salt thereof, and methods for preparing the same. Further, methods of imaging using the radiolabeled triglyceride analog and uses of the radiolabeled triglyceride analog are disclosed herein. The invention also relates to an intermediate triglyceride analog for synthesis of the radiolabeled triglyceride analog.

The present invention belongs to the field of biomedicine and provides radioactive silica microspheres coated with biomedical polymer materials, as well as a preparation method and application thereof. The method comprises the following steps: S1, mixing silica microspheres, water, and a radioactive nuclide to obtain a radioactive silica microsphere mixture; S2, mixing the radioactive silica microsphere mixture with an alkaline solution and reacting to obtain radioactive silica microspheres; S3, mixing the radioactive silica microspheres with a biomedical polymer solution and coating the mixture to obtain radioactive silica microspheres coated with biomedical polymer materials. The preparation method provided by the present invention is simple, and the prepared radioactive silica microspheres coated with biomedical polymer materials have a high radionuclide labeling rate, a low escape rate, good radiostability, and excellent biosafety, and can be used for the embolization treatment of all solid tumors.

The present invention provides hollow borosilicate particulate contrast media for use in CT imaging, comprising a shell material containing less than 8% oxides of non-silicon elements with atomic numbers greater than 10. In an exemplary embodiment, the present invention provides an enteric contrast medium formulation that provides a CT value different from that of water, soft tissue, and fat. An exemplary formulation includes (a) an enteric contrast medium comprising hollow borosilicate microparticles suspended in water. In various embodiments, the hollow borosilicate microparticles are suspended in an aqueous medium with an agent compatible with enteral administration of the formulation to a subject in need of such administration. The present invention also provides a method of imaging the abdomen and pelvis by delivery of hollow borosilicate particulate contrast material to the intestinal lumen and simultaneous CT imaging.